| |
| |
|
| Insider
Information: |
Joshi Abhay |
| Relationship: |
COO, President of R&D |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
120,708 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$410,407 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
120,708 |
|
|
| Total
Value |
$410,407 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Revance Therapeutics, Inc. |
RVNC |
COO, President of R&D |
2022-03-15 |
120,708 |
2015-12-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RVNC |
Revance Therapeutics, Inc... |
COO, President of R&D |
• – – |
2022-03-15 |
4 |
D |
$15.79 |
$41,165 |
D/D |
(2,607) |
120,708 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President, R&D |
• – – |
2022-02-15 |
4 |
D |
$13.35 |
$67,458 |
D/D |
(5,053) |
123,315 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President, R&D |
• – – |
2021-03-15 |
4 |
D |
$27.73 |
$37,546 |
D/D |
(1,354) |
128,368 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President, R&D |
• – – |
2021-02-15 |
4 |
D |
$28.97 |
$140,447 |
D/D |
(4,848) |
129,722 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President, R&D |
• – – |
2021-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,620 |
134,570 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President, R&D |
• – – |
2020-09-30 |
4 |
D |
$25.14 |
$185,583 |
D/D |
(7,382) |
111,950 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President, R&D |
• – – |
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
119,332 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President of R&D |
• – – |
2020-03-15 |
4 |
D |
$15.50 |
$20,987 |
D/D |
(1,354) |
101,832 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
COO, President, R&D |
• – – |
2020-02-15 |
4 |
D |
$25.33 |
$84,222 |
D/D |
(3,325) |
103,186 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
106,511 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2020-01-15 |
4 |
D |
$22.89 |
$101,654 |
D/D |
(4,441) |
81,511 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2019-12-14 |
4 |
D |
$15.99 |
$47,506 |
D/D |
(2,971) |
85,952 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2019-03-15 |
4 |
D |
$15.45 |
$20,919 |
D/D |
(1,354) |
88,923 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2019-03-14 |
4 |
D |
$15.59 |
$2,588 |
D/D |
(166) |
90,277 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2019-03-14 |
4 |
OE |
$4.20 |
$2,797 |
D/D |
666 |
90,443 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2019-02-15 |
4 |
D |
$17.69 |
$26,712 |
D/D |
(1,510) |
89,777 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2019-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
15,750 |
91,287 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2019-01-15 |
4 |
D |
$20.19 |
$90,169 |
D/D |
(4,466) |
75,537 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2018-12-14 |
4 |
D |
$19.91 |
$84,817 |
D/D |
(4,260) |
80,003 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2018-03-21 |
4 |
OE |
$2.55 |
$1,698 |
D/D |
666 |
84,263 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2018-02-15 |
4 |
D |
$31.75 |
$47,911 |
D/D |
(1,509) |
83,597 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2018-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
11,750 |
85,106 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2018-01-15 |
4 |
D |
$34.50 |
$149,282 |
D/D |
(4,327) |
73,356 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2017-12-14 |
4 |
D |
$32.15 |
$103,812 |
D/D |
(3,229) |
77,683 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Operating Officer |
• – – |
2017-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,100 |
80,912 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
